Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 13, 2017 - Issue 10
Submit an article Journal homepage
1,160
Views
27
CrossRef citations to date
0
Altmetric
Review

Lupus nephritis and B-cell targeting therapy

Matthias CassiaNephrology and Immunology Unit, ASST Santi Paolo e Carlo, San Carlo Borromeo Hospital, Milano, Italy;Department of Biomedical and Clinical Sciences “L.Sacco”, University of Milan, Milano, ItalyView further author information
,
Federico AlbericiNephrology and Immunology Unit, ASST Santi Paolo e Carlo, San Carlo Borromeo Hospital, Milano, ItalyCorrespondence[email protected]
View further author information
,
Maurizio GallieniNephrology and Immunology Unit, ASST Santi Paolo e Carlo, San Carlo Borromeo Hospital, Milano, Italy;Department of Biomedical and Clinical Sciences “L.Sacco”, University of Milan, Milano, ItalyView further author information
&
David JayneDepartment of Medicine, University of Cambridge, Cambridge, UKView further author information
Pages 951-962 | Received 01 May 2017, Accepted 09 Aug 2017, Published online: 18 Aug 2017

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Han Zhang, Juan Chen, Ying Zhang, Na Zhao & Dongmei Xu. (2023) Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis. Renal Failure 45:1.
Read now
Tomohiro Koga, Kunihiro Ichinose, Atsushi Kawakami & George C. Tsokos. (2019) The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. Expert Review of Clinical Immunology 15:6, pages 629-637.
Read now

Articles from other publishers (25)

Bruno Brando & Arianna Gatti. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal 347 374 .
Ryan M. Baxter, Christine S. Wang, Josselyn E. Garcia-Perez, Daniel S. Kong, Brianne M. Coleman, Valentyna Larchenko, Ronald P. Schuyler, Conner Jackson, Tusharkanti Ghosh, Pratyaydipta Rudra, Debdas Paul, Manfred Claassen, Rosemary Rochford, John C. Cambier, Debashis Ghosh, Jennifer C. Cooper, Mia J. Smith & Elena W. Y. Hsieh. (2023) Expansion of extrafollicular B and T cell subsets in childhood-onset systemic lupus erythematosus. Frontiers in Immunology 14.
Crossref
Yingkun Nie, Chunyan Li & Ni Sun. (2023) Ophiopogonin D attenuates the progression of murine systemic lupus erythematosus by reducing B cell numbers. Journal of Biochemical and Molecular Toxicology 37:7.
Crossref
寒 孔. (2023) Application of Belizumab in Lupus Nephritis. Advances in Clinical Medicine 13:05, pages 8421-8430.
Crossref
Ruilin Chen, Rong Fu, Zeying Lin, Chenghui Huang & Wenhui Huang. (2022) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus 32:1, pages 94-100.
Crossref
Marta de la Rubia Navarro, José Rafael Ivorra Cortés, Elena Grau García & José Andrés Román Ivorra. (2022) Efectividad de belimumab en el tratamiento de la nefritis lúpica: análisis de 8 casos. Medicina Clínica 159:7, pages 344-346.
Crossref
Marta de la Rubia Navarro, José Rafael Ivorra Cortés, Elena Grau García & José Andrés Román Ivorra. (2022) Effectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases. Medicina Clínica (English Edition) 159:7, pages 344-346.
Crossref
Ali AlSahow, Abdullah Al-Muhaiteeb, Hani Nawar, Bassam AlHelal, Anas AlYousef, Emad Abdallah, Ahmad AbuShall, Sameh Elmekawi, Basem Meshal, Ahmed AlQallaf & Heba AlRajab. (2022) Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective. Medical Principles and Practice 31:2, pages 133-141.
Crossref
Yaxi Li, Hongting Wang, Zijing Zhang, Chenling Tang, Xinjin Zhou, Chandra Mohan & Tianfu Wu. (2022) Identification of polo‐like kinase 1 as a therapeutic target in murine lupus. Clinical & Translational Immunology 11:1.
Crossref
Yutong Zou, Fang Liu, Mark E. Cooper & Zhonglin Chai. (2021) Advances in clinical research in chronic kidney disease. Journal of Translational Internal Medicine 9:3, pages 146-149.
Crossref
Lei Shen, Xiangying Liu, Ci Sun, Guoyuan Lu, Ling Zhou & Jianzhong Li. (2021) Rituximab therapy for lupus nephritis: A meta‑analysis. World Academy of Sciences Journal 3:5.
Crossref
Arianna Gatti, Francesco Buccisano, Maria T. Scupoli & Bruno Brando. (2020) The ISCCA flow protocol for the monitoring of anti‐CD20 therapies in autoimmune disorders. Cytometry Part B: Clinical Cytometry 100:2, pages 194-205.
Crossref
Tomohiro Koga, Kunihiro Ichinose, Atsushi Kawakami & George C. Tsokos. (2021) Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus. Frontiers in Immunology 11.
Crossref
Margarida Matos Bela, Gerard Espinosa & Ricard Cervera. (2020) Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus 30:1, pages 134-140.
Crossref
Meera Ramanujam, Jürgen Steffgen, Sudha Visvanathan, Chandra Mohan, Jay S. Fine & Chaim Putterman. (2020) Phoenix from the flames: Rediscovering the role of the CD40–CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmunity Reviews 19:11, pages 102668.
Crossref
Anna Wardowska, Michał Komorniczak, Aneta Skoniecka, Barbara Bułło-Piontecka, Katarzyna A. Lisowska, M.Alicja Dębska-Ślizień & Michał Pikuła. (2020) Alterations in peripheral blood B cells in systemic lupus erythematosus patients with renal insufficiency. International Immunopharmacology 83, pages 106451.
Crossref
Joana Eugénio Santos, David Fiel, Ricardo Santos, Rita Vicente, Rute Aguiar, Iolanda Santos, Manuel Amoedo & Carlos Pires. (2020) Rituximab use in adult glomerulopathies and its rationale. Brazilian Journal of Nephrology 42:1, pages 77-93.
Crossref
Qihang Yuan, Haifeng Chen, Xia Li & Jing Wei. (2019) Leptin: an unappreciated key player in SLE. Clinical Rheumatology 39:2, pages 305-317.
Crossref
Martina Tedesco, Maurizio Gallieni, Francesca Pellegata, Mario Cozzolino & Federico Alberici. (2019) Update on ANCA-associated vasculitis: from biomarkers to therapy. Journal of Nephrology 32:6, pages 871-882.
Crossref
Chin Hee Mun, Jin-Ock Kim, Sung Soo Ahn, Taejun Yoon, Su Jeong Kim, Eunhee Ko, Hee-Dong Noh, Yong-Beom Park, Hak-Jun Jung, Tae Sung Kim, Sang-Won Lee & Sang Gyu Park. (2019) Atializumab, a humanized anti-aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) antibody significantly improves nephritis in (NZB/NZW) F1 mice. Biomaterials 220, pages 119408.
Crossref
Matthias A. Cassia, Federico Alberici, Rachel B. Jones, Rona M. Smith, Giovanni Casazza, Maria L. Urban, Giacomo Emmi, Gabriella Moroni, Renato A. Sinico, Piergiorgio Messa, Frances Hall, Augusto Vaglio, Maurizio Gallieni & David R. Jayne. (2019) Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. Arthritis & Rheumatology 71:10, pages 1670-1680.
Crossref
Andrés A. Herrada, Noelia Escobedo, Mirentxu Iruretagoyena, Rodrigo A. Valenzuela, Paula I. Burgos, Loreto Cuitino & Carolina Llanos. (2019) Innate Immune Cells' Contribution to Systemic Lupus Erythematosus. Frontiers in Immunology 10.
Crossref
Kongyang Ma, Jingyi Li, Xiaohui Wang, Xiang Lin, Wenhan Du, Xi Yang, Fangxiang Mou, Yongfei Fang, Yanbin Zhao, Xiaoping Hong, Kwok Wah Chan, Xiaoming Zhang, Dongzhou Liu, Lingyun Sun & Liwei Lu. (2018) TLR4 + CXCR4 + plasma cells drive nephritis development in systemic lupus erythematosus . Annals of the Rheumatic Diseases 77:10, pages 1498-1506.
Crossref
Shreeya Patel, Laura Ross, Shereen Oon & Mandana Nikpour. (2018) Rituximab treatment in primary angiitis of the central nervous system. Internal Medicine Journal 48:6, pages 724-727.
Crossref
Daniel Ricklin, Dimitrios C. Mastellos, Edimara S. Reis & John D. Lambris. (2017) The renaissance of complement therapeutics. Nature Reviews Nephrology 14:1, pages 26-47.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.